Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297349 | 0.93 | DDB1 (0.44) | DDB1CRBN | |
| SCHEMBL6299054 | 0.85 | DDB1 (0.46) | DDB1CRBN | |
| SCHEMBL3524295 | 0.83 | MAOA (0.38) | DDB1CRBN | |
| SCHEMBL3524293 | 0.83 | MAOA (0.38) | DDB1CRBN | |
| SCHEMBL4272254 | 0.80 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL27675507 | 0.80 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL4609023 | 0.80 | DDB1 (0.54) | DDB1CRBN | |
| SCHEMBL10554096 | 0.78 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL10555922 | 0.78 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL20156647 | 0.78 | DDB1 (0.46) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1541174-A1 | DRUG OR COSMETIC | Ishibashi, Michio (JP) | 2005-06-15 | — | — | EP | claimed |
| EP-1950563-A2 | Method for screening for a substance for promoting regeneration of macrophages | Ishibashi, Michio (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20060014709-A1 | Drug or cosmetic | ISHIBASHI MICHIO | 2006-01-19 | — | — | US | disclosed |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | ISHIBASHI MICHIO (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1541174-A1 | DRUG OR COSMETIC | Ishibashi, Michio (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6878745-B2 | Selective preventives/remedies for progressive lesions after organ damage | Ishibashi, Michio (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | DDB1 495/4885CRBN 4234/4885 |
| US-20060014709-A1 | Drug or cosmetic | CTSA, MSR1, CD68 | DDB1 1553/4885CRBN 3936/4885 |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | CD68, MSR1, CCL2 | DDB1 578/4885CRBN 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.